At Market Issuance Sales AgreementAt Market Issuance Sales Agreement • May 7th, 2021 • Entera Bio Ltd. • Biological products, (no disgnostic substances) • New York
CONVERTIBLE NOTE DUE JULY 1, 2018Convertible Security Agreement • January 18th, 2017 • Aethlon Medical Inc • Laboratory analytical instruments • New York
THIS CONVERTIBLE NOTE is one of a series of duly authorized and validly issued Notes of AETHLON MEDICAL, INC., a Nevada corporation, (the “Borrower”), having its principal place of business at 9635 Granite Ridge Drive, Suite 100, San Diego, CA 92123, Fax: 858-272-2738, due July 1, 2018 (this note, the “Note” and, collectively with the other notes of such series, the “Notes”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • January 18th, 2017 • Aethlon Medical Inc • Laboratory analytical instruments • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of December 30, 2016, between Aethlon Medical, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a “Purchaser” and collectively, the “Purchasers”).
IBIS TECHNOLOGY CORPORATION UNDERWRITING AGREEMENTUnderwriting Agreement • October 16th, 2003 • Ibis Technology Corp • Semiconductors & related devices • New York
Ibis Technology Corporation, a Massachusetts corporation (the "Company"), proposes to sell (the "Offering"), upon the terms and subject to the conditions of this Agreement, to CDC Securities (the "Underwriter"), an aggregate of 870,000 shares (the "Firm Shares") of the Company's common stock, par value $.008 per share ("Common Stock"). The Company also proposes to sell to the Underwriter, at the option of the Underwriter, an aggregate of not more than 130,000 additional shares of the Company's Common Stock (such additional shares being hereinafter referred to as the "Optional Shares"). The Firm Shares and the Optional Shares are herein collectively called the "Offered Shares."
